Molecular Partners AG (SWX:MOLN)
4.200
+0.035 (0.83%)
Mar 3, 2025, 5:31 PM CET
Molecular Partners AG Employees
Molecular Partners AG had 168 employees as of December 31, 2023. The number of employees decreased by 8 or -4.45% compared to the previous year.
Employees
168
Change (1Y)
-8
Growth (1Y)
-4.45%
Revenue / Employee
35.73K CHF
Profits / Employee
-372.57K CHF
Market Cap
154.87M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Roche Holding AG | 103,249 |
Novartis AG | 75,883 |
Alcon | 25,599 |
Lonza Group AG | 18,686 |
Galderma Group AG | 6,545 |
Straumann Holding AG | 11,815 |
Sandoz Group AG | 22,633 |
Sonova Holding AG | 18,151 |
Molecular Partners AG News
- 6 weeks ago - Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs - Seeking Alpha
- 7 weeks ago - Molecular Partners & Orano Med join hands for alpha radio-therapies for cancer - Seeking Alpha
- 7 weeks ago - Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer - GlobeNewsWire
- 2 months ago - Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January - GlobeNewsWire
- 3 months ago - Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 - GlobeNewsWire
- 4 months ago - Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 - GlobeNewsWire
- 4 months ago - Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going - GlobeNewsWire